Greenwich LifeSciences
GLSI
34 hedge funds and large institutions have $18.3M invested in Greenwich LifeSciences in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 7 closing their positions.
1.12% more ownership
Funds ownership: 6.07% → 7.19% (+1.1%)
3% less funds holding
Funds holding: 35 → 34 (-1)
6% less capital invested
Capital invested by funds: $19.4M → $18.3M (-$1.11M)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.55M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$280K |
| 3 |
Nisa Investment Advisors
St. Louis,
Missouri
|
+$146K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$64.4K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$62.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$740K |
| 2 |
Renaissance Technologies
New York
|
-$730K |
| 3 |
HF
HRT Financial
New York
|
-$388K |
| 4 |
Morgan Stanley
New York
|
-$292K |
| 5 |
D.E. Shaw & Co
New York
|
-$254K |
GLSI Hedge Fund Activity: Q1 2022 in Review
34 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Greenwich LifeSciences (GLSI) for Q1 2022, worth a combined $18.3M — down 5.7% from $19.4M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of GLSI and 6 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 8 added.
The largest buyer was Vanguard Group, adding an estimated $4.55M. The largest seller was Millennium Management, exiting entirely with an estimated $740K sold.
- 34 institutional investors held Greenwich LifeSciences (GLSI) as of Q1 2022, down from 35 in Q4 2021.
- Funds reported $18.3M of Greenwich LifeSciences stock for Q1 2022, down 5.7% quarter-over-quarter.
- 6 funds opened new Greenwich LifeSciences positions in Q1 2022 and 7 closed out, a net change of -1 holder.
- The largest Greenwich LifeSciences buyer in Q1 2022 was Vanguard Group, an estimated $4.55M added.
- The largest Greenwich LifeSciences seller in Q1 2022 was Millennium Management, an estimated $740K sold.
Based on aggregated 13F filings for Q1 2022.